Abstract:
Clinical outcomes of patients with nasopharyngeal carcinoma have improved after radiotherapy and concurrent adjuvant chemotherapy. However, tumor recurrence and distant metastasis remain a problem. In recent years, immune checkpoint inhibitors have provided new options for tumor immunotherapy. Among immune checkpoint inhibitors, programmed cell death protein-1 (PD-1)/ programmed cell death protein-ligand 1 (PD- L1) monoclonal antibodies have received widespread attention and have been used in clinical treatments. This article reviews the research progress of pembrolizumab, nivolizumab, carrelizumab, teriprizumab, and other PD-1/PD-L1 monoclonal antibodies in recurrent/metastatic nasopharyngeal carcinoma.